Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TAC-101 with TACE in Advanced Hepatocellular Carcinoma
NCT00756782Phase 2Withdrawn
- Sponsor
- Taiho Oncology
- Start
- Oct 2008
- Primary completion
- Dec 2008
- Modality
- Small Molecules
01
Overview
A Phase 2 trial of TAC-101 in hepatocellular carcinoma (HCC), sponsored by Taiho Oncology. Planned start Oct 2008; status: withdrawn.
02
Drugs
TAC-101
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on NCT00756782.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00756782.